FBLG — FibroBiologics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1958777 ·
Last close
$1.35
Market Cap
$8.99M
52W High
$1.50
52W Low
$0.62
ADV30
190,602
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -4,033,000 | -4,117,000 | 7,929,000 | 3,515,000 | 3,293,000 |
| Mar 2026 | 0 | — | -5,068,000 | -5,000,000 | 5,938,000 | 1,482,000 | 3,338,000 |
| Dec 2025 | 0 | — | -2,590,000 | -3,244,000 | 9,619,000 | 4,894,000 | 3,463,000 |
| Sep 2025 | 0 | — | -5,038,000 | -5,778,000 | 8,744,000 | 4,867,000 | 8,619,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,483,000
Investing CF
$-219,000
Financing CF
$8,517,000
CapEx
$-361,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-9.04
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-59,164,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-18,472,000
Pretax Income TTM
$-18,680,000
Interest Exp TTM
$208,000
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -16,649,000 | -18,646,000 | 9,619,000 | 3,463,000 | — | -16,394,000 |
| Dec 2024 | 0 | -13,737,000 | -11,161,000 | 16,445,000 | 13,710,000 | — | -11,901,000 |
| Dec 2023 | 0 | -8,889,000 | -16,485,000 | 11,821,000 | 10,568,000 | — | -6,401,000 |
| Dec 2022 | 0 | -4,467,000 | -5,121,000 | 4,824,000 | 8,820,000 | — | -4,066,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.25
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMRN | Immuron Ltd | $9.04M | $1.12 | — |
| XBIO | Xenetic Biosciences, Inc. | $8.93M | $3.81 | — |
| IMNN | Imunon, Inc. | $8.92M | $1.59 | — |
| AZTR | Azitra, Inc. | $9.11M | $0.15 | — |
| SNGX | SOLIGENIX, INC. | $8.81M | $0.40 | — |
News headlines (Yahoo Finance, 1h cache)
FibroBiologics Appoints Leigh Steinberg to Board of Directors
2026-08-24 12:30 · Yahoo
FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints
2026-08-18 12:30 · Yahoo
FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage
2026-08-05 12:30 · Yahoo
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
2026-07-31 21:34 · Yahoo
FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors
2026-07-09 12:30 · Yahoo
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
2026-07-07 12:30 · Yahoo
FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
2026-06-30 12:30 · Yahoo
FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
2026-06-29 20:01 · Yahoo
FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
2026-06-26 12:30 · Yahoo
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
2026-06-22 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.